Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone
| Autor: | Bouranta P, Bourantas Kl, Mary Gouva, Bourantas D, Amalia Vassou, Alymara, Tzouvara E, Aristeidis Chaidos |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Pyridones Iron Injections Subcutaneous Urinary system Administration Oral Deferoxamine Neutropenia Iron Chelating Agents Ferritins/blood/drug effects Gastroenterology Drug Administration Schedule Excretion chemistry.chemical_compound Iron/urine Internal medicine Pyridones/*administration & dosage/adverse effects medicine Humans Deferiprone Deferoxamine/*administration & dosage/adverse effects Iron Chelating Agents/*administration & dosage/adverse effects Hematology Dose-Response Relationship Drug business.industry beta-Thalassemia Middle Aged medicine.disease Surgery Treatment Outcome beta-Thalassemia/*drug therapy chemistry Taste disorder Ferritins Toxicity Drug Therapy Combination Female business medicine.drug |
| Zdroj: | The Hematology Journal. 5:475-479 |
| ISSN: | 1476-5632 1466-4860 |
| Popis: | Introduction: The purpose of our study was to evaluate the effectiveness and safety of combined therapy with deferoxamine (DFO) and deferiprone (DFP) in patients with b-thalassemia major and increased serum ferritin. Patients and methods: Our study was performed in 36 patients with b-thalassemia major. DFP was administered orally in a total daily dose of 60 mg/kg for 6 days per week and DFO was administered subcutaneously in a total daily dose of 40–50 mg/kg for 4–6 days per week. The efficacy of combined treatment was assessed by measurements of serum ferritin and 24-h urine iron excretion levels. Results: Out of the 36 patients, 11 discontinued DFO after a mean of 4 months; however, 25 patients, who continued to receive the combined therapy showed a very satisfactory compliance. After a mean of 13.5 months, their mean serum ferritin levels reduced from 263771292 to 158071024 ng/ml (P ¼ 0.002) and their mean urinary iron excretion elevated from 0.4170.27 to 0.7670.49 mg/24 h (P ¼ 0.003). The observed side effects were gastrointestinal disorders, elevations in liver enzymes, mild neutropenia, joint symptoms, taste disorders, dizziness and fatigue. Conclusions: The results of this study show that combined iron-chelation therapy with DFO and DFP results in satisfactory reduction of serum ferritin with no significant toxicity. The Hematology Journal (2004) 5, 475–479. doi:10.1038/sj.thj.6200550 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|